Cargando…
Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy
Chronic heart failure (HF) is a major cause of morbidity and mortality particularly in the elderly and a growing healthcare burden in Italy. The objective was to assess the cost-effectiveness of candesartan cilexetil, an angiotensin II type 1 receptor blocker (ARB) for the treatment of HF. A pre-spe...
Autores principales: | Colombo, Giorgio L, Caruggi, Mauro, Ottolini, Chiara, Maggioni, Aldo P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464765/ https://www.ncbi.nlm.nih.gov/pubmed/18629370 |
Ejemplares similares
-
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
por: Preiss, David, et al.
Publicado: (2009) -
Burden of Crohn’s disease: economics and quality of life aspects in Italy
por: Benedini, Viviano, et al.
Publicado: (2012) -
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
por: Dubé, Marie‐Pierre, et al.
Publicado: (2022) -
Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
por: Ravangard, Ramin, et al.
Publicado: (2023) -
Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2021)